Chemo and targeted therapy before surgery for recurrent colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery for colorectal cancer before and it was completely removed.
- Your cancer came back in the same area (locally), not spread to other organs.
- You have not had any cancer treatment (chemo, targeted therapy, immunotherapy, or radiation) in the last month.
- You are in reasonably good health (able to care for yourself) and your organs are working well.
- You have not had immunotherapy with drugs like anti-PD1 or anti-CTLA4 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This Phase 3 study compares two schedules of a colon cancer chemo combination: starting before surgery or starting after surgery. It aims to see which timing helps people live longer and lowers cancer coming back.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
This trial tests a combination of three drugs (serplulimab, CAPOX, and bevacizumab) given before surgery to shrink locally advanced rectal cancer. The goal is to make the tumor easier to remove and potentially improve outcomes.
This trial tests a combination of drugs before surgery for locally advanced colorectal cancer. The goal is to see if this treatment shrinks the tumor and improves surgical outcomes.
Hear when a new Locally Recurrent Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.